

# Working to end the epidemic.

## HIV Pipeline\*





Clinical Program





Indication

Phase




### HIV Prevention

Lenacapavir (Purpose 1 & 2)	HIV PrEP LAI		NDA & EC approved	EC Approved
Lenacapavir (PURPOSE 365)	HIV PrEP LAI			

### HIV Treatment

Bictegravir/lenacapavir oral combination (ARTISTRY-1 & -2)	HIV Oral			
Islatravir/lenacapavir oral combination (ISLEND-1 & -2) <sup>1</sup>	HIV LAO			
Lenacapavir + teropavimab + zinlirvimab	HIV LAI			Breakthrough Therapy Designation
HIV INSTI (GS-1219)	HIV LAI			
HIV capsid inhibitor (GS-3107)	HIV LAO			
HIV INSTI (GS-3242)	HIV LAI			

### HIV Cure

Teropavimab + zinlirvimab <sup>2,3</sup>	HIV Cure			
Vesatolimod (FRESH)	HIV Cure			
HIV bispecific T-cell engager (GS-8588)	HIV Cure			

\*As reported in Gilead's Q3 2025 Earnings Statement.  
 1. Subject to Gilead and Merck co-development and co-commercialization agreement. 2. Teropavimab and zinlirvimab are broadly neutralizing antibody (bNAbs). 3. Non-Gilead sponsored trial(s) ongoing.  
 HIV - human immunodeficiency virus, INSTI - integrase strand transfer inhibitor, LAI - long-acting injectable, LAO - long-acting oral, NDA - new drug application, NRTTI - nucleoside reverse transcriptase translocation inhibitor, PrEP - pre-exposure prophylaxis, FPI - first patient in.